Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00647608 | Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg | PHASE1 | COMPLETED | 98 | — | — | Sep 1, 2005 | Oct 1, 2005 | Apr 24, 2024 | 1 | United States |
| NCT00647816 | Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg | PHASE1 | COMPLETED | 100 | — | — | Sep 1, 2005 | Sep 1, 2005 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Propranolol Hydrochloride Extended-Release Capsules 160 mg |
| 2 | ACTIVE_COMPARATOR | Inderal® LA Capsules 160 mg |
| Name | Type | Description |
|---|---|---|
| Propranolol Hydrochloride Extended-Release Capsules 160 mg | DRUG | 160mg, single dose fed |
| Inderal® LA Capsules 160 mg | DRUG | 160mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum (Beta HCG) pregnancy test performed within 21 days prior to the start of the study and on the evening prior to each dose administ...